wholesalemedicine.org

Roche / Bonviva

About Bonviva

• Bonviva, a potent bisphosphonate, has been studied to date in clinical trials involving over 11,000 patients.
• The ongoing clinical development programme is evaluating monthly oral and bi-monthly/quarterly intravenous dosage regimens in women with postmenopausal osteoporosis.
• Bonviva, indicated in Europe as a daily formulation for the treatment and prevention of osteoporosis in postmenopausal women, reduces bone turnover, increases bone mineral density and reduces the incidence of vertebral fractures.
• The U.S. Food and Drug Administration gave approval for once-monthly Boniva in March 2005. Boniva has been available in the US since late April 2005.
• Bonviva is the only bisphosphonate that has demonstrated a reduction in vertebral fracture risk using a drug-free interval of more than one week.12
Studies specifically designed to demonstrate reductions in non-vertebral or hip fractures have not been conducted with Bonviva.
• Bonviva, like other orally administered bisphosphonates, may cause upper gastrointestinal disorders such as dysphagia, esophagitis and esophageal or gastric ulcer.